On This Page Date: June 3 – 5, 2024 Day1: Mon, Jun 3 9:00 AM – 6:00 PM ET Day2: Tue, Jun 4 9:00 AM – […]

For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the […]

Docket Number: FDA-2004-D-0241 Issued by: Guidance Issuing Office Center for Biologics Evaluation and Research Center for Drug Evaluation and Research This guidance provides recommendations to sponsors […]

Reference #: NDA 212122 Product: Drugs Recipient: Recipient Name Inna Kissen, Ph.D. Recipient Title Senior Director, Promotional Regulatory Affairs AstraZeneca Pharmaceuticals LP 1800 Concord PikeWilmington, DE […]

Product: Drugs Recipient: Recipient Name Pascal Soriot Recipient Title Executive Director and Chief Executive Officer AstraZeneca Pharmaceuticals LP 1800 Concord PikeWilmington, DE 19850United States Issuing Office: […]

FDA’s Bad Ad Program is an outreach program designed to help healthcare providers recognize potentially false or misleading prescription drug promotion. The program’s goal is to […]

Office of Prescription Drug Promotion Content current as of: 05/31/2024 Regulated Product(s)